APGE
Apogee Therapeutics, Inc.Company Information
- Company Name
- Apogee Therapeutics, Inc.
- CIK
- CIK0001974640
- Category
- Large accelerated filer
- Ticker: Exchange
- APGE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- APGE
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-12
- Last sale
- 2026-08-05
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 2,187,345
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 65,028,637
- Shares outstanding
- 75,443,496
- Ownership
- 86.20%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series Preferred Units | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Series B Preferred Units | - | - | - | - | - | - | - | - | - | - | 0 | 34 | ||||||
Assets Current | ||||||||||||||||||
| Cash Equivalents At Carrying Value | 106 | 452 | 132 | 108 | 124 | 107 | 142 | 119 | 307 | 485 | 118 | 188 | ||||||
| Marketable Securities Current | 866 | 608 | 599 | 419 | 381 | 406 | 379 | 407 | 369 | 331 | 277 | 235 | ||||||
| Prepaid Expense And Other Assets Current | 20 | 14 | 11 | 13 | 11 | 8 | 9 | 8 | 6 | 4 | 3 | 4 | ||||||
| Assets Current | 992 | 1,074 | 741 | 540 | 516 | 522 | 530 | 534 | 682 | 821 | 398 | 426 | ||||||
| Marketable Securities Noncurrent | 322 | 198 | 173 | 62 | 116 | 168 | 210 | 228 | 113 | - | - | - | ||||||
| Property Plant And Equipment Net | 5 | 5 | 6 | 6 | 6 | 6 | 2 | 1 | 1 | 1 | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 7 | 8 | 9 | 10 | 11 | 12 | 11 | 12 | 4 | 2 | 2 | - | ||||||
| Other Assets Noncurrent | 11 | 9 | 9 | 9 | 9 | 7 | 0 | 1 | 0 | 0 | 0 | - | ||||||
| Assets | 1,336 | 1,294 | 937 | 626 | 658 | 714 | 754 | 776 | 801 | 824 | 401 | 426 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 1 | 1 | 0 | 6 | 2 | 1 | 2 | 6 | 4 | 2 | 1 | ||||||
| Operating Lease Liability Current | 2 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 1 | 1 | - | ||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | 28 | 17 | 16 | 17 | 16 | ||||||
| Liabilities Current | 38 | 33 | 28 | 34 | 32 | 33 | 29 | 33 | 25 | 22 | 21 | 17 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 4 | 5 | 5 | 6 | 7 | 8 | 9 | 9 | 2 | 1 | 1 | - | ||||||
| Liabilities | 141 | 38 | 33 | 40 | 38 | 41 | 37 | 42 | 27 | 22 | 21 | 17 | ||||||
Limited Liability Company L L C Members Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Additional Paid In Capital | 1,919 | 1,892 | 1,465 | 1,078 | 1,046 | 1,034 | 1,022 | 970 | 964 | 958 | 503 | 501 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -1 | 1 | 1 | 1 | 1 | 1 | 3 | -0 | -0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -722 | -636 | -562 | -492 | -427 | -361 | -306 | -239 | -190 | -156 | -124 | -92 | ||||||
| Members Equity | 1,195 | 1,256 | 904 | 586 | 619 | 673 | 717 | 734 | 774 | 801 | 380 | 409 | ||||||
| Liabilities And Stockholders Equity | 1,336 | 1,294 | 937 | 626 | 658 | 714 | 754 | 776 | 801 | 824 | 401 | 426 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 76 | 75 | 69 | 60 | 60 | 60 | 59 | 59 | 58 | 58 | 51 | 51 | ||||||
| Shares Outstanding | 75 | 75 | 68 | 59 | 59 | 58 | 58 | 57 | 57 | 56 | 48 | 48 | ||||||
| Common Unit Authorized | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Unit Issued | - | - | - | - | - | - | - | - | - | - | 0 | 5 | ||||||
| Common Unit Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | 5 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | 10 | 10 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialApogee Therapeutics, Inc. (APGE) — SEC Financial Statements & Analysis
Apogee Therapeutics, Inc. (APGE) is a biological products, (no diagnostic substances) company. Apogee Therapeutics, Inc. trades on Nasdaq as: APGE. Apogee Therapeutics, Inc. (APGE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Apogee Therapeutics, Inc. carries a market cap of $10.01B, a P/E ratio of -34.02x, a P/B ratio of 8.38x, an enterprise value of $9.91B, and an EV/EBITDA multiple of -30.35x. On profitability, it posts a Return on Equity (ROE) of -32.46%, a Return on Assets (ROA) of -29.53%, and a Return on Invested Capital (ROIC) of -41.39%. Per share, it reports EPS of $-3.90, diluted EPS of $-3.90, free cash flow per share of $-3.23, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 23.86% year-over-year and EPS growth of -4.08% year-over-year. On the balance sheet, it maintains a current ratio of 26.44x, a quick ratio of 25.91x, working capital of $954.22M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, an interest coverage ratio of -207.66x, free cash flow of $-243.96M (TTM), and net debt of $-105.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $10.01B
- P/E TTM
- -34.02x
- EPS TTM
- $-3.90
- P/B TTM
- 8.38x
- ROE TTM
- -32.46%
- ROA TTM
- -29.53%
- Debt To Equity
- 0.12x
- Free Cash Flow TTM
- $-243.96M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Apogee Therapeutics, Inc. in?
Apogee Therapeutics, Inc. (APGE) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does APGE trade on?
Apogee Therapeutics, Inc. (APGE) trades on the Nasdaq.
When was Apogee Therapeutics, Inc. (APGE)'s most recent SEC filing?
Apogee Therapeutics, Inc. (APGE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is APGE's market cap?
Apogee Therapeutics, Inc. (APGE) has a market capitalization of $10.01B as of 2026-06-30.
What is APGE's EPS (earnings per share)?
Apogee Therapeutics, Inc. (APGE)'s trailing twelve month EPS is $-3.90 as of 2026-06-30.
What is APGE's ROE (return on equity)?
Apogee Therapeutics, Inc. (APGE)'s trailing twelve month Return on Equity (ROE) is -32.46% as of 2026-06-30.
What is APGE's ROA (return on assets)?
Apogee Therapeutics, Inc. (APGE)'s trailing twelve month Return on Assets (ROA) is -29.53% as of 2026-06-30.
What is APGE's ROIC (return on invested capital)?
Apogee Therapeutics, Inc. (APGE)'s trailing twelve month Return on Invested Capital (ROIC) is -41.39% as of 2026-06-30.
What is APGE's EV/EBITDA?
Apogee Therapeutics, Inc. (APGE)'s trailing twelve month EV/EBITDA is -30.35x as of 2026-06-30.